Overview Dividends

(HCA) HCA Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40412C1018

Hospital, Outpatient, Surgery, Emergency, Psychiatry

Health Care Facilities
Market Cap in USD: 111,446m

IPO / Inception: 2011-03-10
Return 12m vs S&P 500: 36.4%

EPS (Earnings per Share)

EPS CAGR: 12.87%
EPS Trend: 85.5%

Last SUE: 3.43
Qual. Beats: 3

Revenue

Rev. CAGR: 6.63%
Rev. Trend: 97.8%

Last SUE: 1.97
Qual. Beats: 1

Dividends

Dividend Yield	0.70%
Yield on Cost 5y	2.46%
Yield CAGR 5y	36.07%
Payout Consistency	53.8%
Payout Ratio	10.9%

Risk via 10d forecast
Volatility	26.7%
Value at Risk 5%th	43.2%
Relative Tail Risk	-1.85%

Reward TTM
Sharpe Ratio	1.63
Alpha	49.66
CAGR/Max DD	1.05

Character TTM
Hurst Exponent	0.553
Beta	0.303
Beta Downside	0.414

Drawdowns 3y
Max DD	28.45%
Mean DD	8.34%
Median DD	5.53%

Description: HCA HCA Holdings September 25, 2025

HCA Healthcare, Inc. (NYSE:HCA) operates a nationwide network of general-acute hospitals and a broad suite of outpatient facilities, ranging from freestanding surgery centers and urgent-care clinics to behavioral health hospitals and oncology centers. Its service portfolio spans inpatient care (including intensive-care, cardiac, and emergency services) and outpatient offerings such as radiology, laboratory, physical therapy, and physician practice management.

As of the end of FY 2023, HCA reported revenue of roughly **$15.6 billion**, with an adjusted operating margin near **7 %**-a level that reflects both the scale efficiencies of its integrated model and the cost pressures from a tight labor market. The company now runs **over 190 hospitals** and **more than 2,000 outpatient sites**, serving a patient mix that is approximately 55 % commercial, 30 % Medicare, and 15 % Medicaid.

Key economic drivers for HCA include the aging U.S. population, which is expanding demand for acute-care and chronic-disease management, and the ongoing shift toward outpatient and same-day procedures that improve throughput and reduce per-case costs. Conversely, inflation-driven labor shortages and potential regulatory changes to Medicare reimbursement pose downside risk to margins.

Given these dynamics, a thorough scenario-based valuation can help isolate the impact of payer mix shifts, labor-cost inflation, and outpatient-care growth on HCA’s future cash flows. For a deeper dive into HCA’s valuation metrics and scenario analysis, you may find the research tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (6.38b TTM) > 0 and > 6% of Revenue (6% = 4.46b TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 3.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -3.51% (prev 2.53%; Δ -6.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.21 (>3.0%) and CFO 12.84b > Net Income 6.38b (YES >=105%, WARN >=100%)

Net Debt (45.35b) to EBITDA (15.00b) ratio: 3.02 <= 3.0 (WARN <= 3.5)

Current Ratio 0.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (242.5m) change vs 12m ago -6.72% (target <= -2.0% for YES)

Gross Margin 15.64% (prev 15.08%; Δ 0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 124.8% (prev 117.1%; Δ 7.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.23 (EBITDA TTM 15.00b / Interest Expense TTM 2.20b) >= 6 (WARN >= 3)

Altman Z'' 0.65

(A) -0.04 = (Total Current Assets 15.29b - Total Current Liabilities 17.90b) / Total Assets 59.75b

(B) -0.08 = Retained Earnings (Balance) -5.03b / Total Assets 59.75b

(D) -0.09 = Book Value of Equity -5.33b / Total Liabilities 61.91b

Total Rating: 0.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.12

1. Piotroski 7.50pt

2. FCF Yield 5.16%

3. FCF Margin 10.89%

4. Debt/Equity -8.69

5. Debt/Ebitda 3.02

6. ROIC - WACC (= 17.31)%

7. RoE -161.9%

8. Rev. Trend 97.85%

9. EPS Trend 85.50%

What is the price of HCA shares?

As of November 30, 2025, the stock is trading at USD 508.29 with a total of 528,537 shares traded.
Over the past week, the price has changed by +3.52%, over one month by +8.97%, over three months by +25.02% and over the past year by +56.60%.

Is HCA a buy, sell or hold?

HCA Holdings has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy HCA.

Strong Buy: 13
Buy: 2
Hold: 9
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HCA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	477.7	-6%
Analysts Target Price	477.7	-6%
ValueRay Target Price	677.1	33.2%

HCA Fundamental Data Overview November 22, 2025

Market Cap USD = 111.45b (111.45b USD * 1.0 USD.USD)
P/E Trailing = 18.4034
P/E Forward = 16.2338
P/S = 1.4985
P/B = 293.44
P/EG = 1.2821
Beta = 1.376
Revenue TTM = 74.37b USD
EBIT TTM = 11.53b USD
EBITDA TTM = 15.00b USD
Long Term Debt = 38.40b USD (from longTermDebt, last quarter)
Short Term Debt = 6.11b USD (from shortTermDebt, last quarter)
Debt = 46.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.35b USD (from netDebt column, last quarter)
Enterprise Value = 156.80b USD (111.45b + Debt 46.35b - CCE 997.0m)
Interest Coverage Ratio = 5.23 (Ebit TTM 11.53b / Interest Expense TTM 2.20b)
FCF Yield = 5.16% (FCF TTM 8.10b / Enterprise Value 156.80b)
FCF Margin = 10.89% (FCF TTM 8.10b / Revenue TTM 74.37b)
Net Margin = 8.57% (Net Income TTM 6.38b / Revenue TTM 74.37b)
Gross Margin = 15.64% ((Revenue TTM 74.37b - Cost of Revenue TTM 62.74b) / Revenue TTM)
Gross Margin QoQ = 15.47% (prev 15.95%)
Tobins Q-Ratio = 2.62 (Enterprise Value 156.80b / Total Assets 59.75b)
Interest Expense / Debt = 1.21% (Interest Expense 561.0m / Debt 46.35b)
Taxrate = 21.06% (516.0m / 2.45b)
NOPAT = 9.10b (EBIT 11.53b * (1 - 21.06%))
Current Ratio = 0.85 (Total Current Assets 15.29b / Total Current Liabilities 17.90b)
Debt / Equity = -8.69 (negative equity) (Debt 46.35b / totalStockholderEquity, last quarter -5.33b)
Debt / EBITDA = 3.02 (Net Debt 45.35b / EBITDA 15.00b)
Debt / FCF = 5.60 (Net Debt 45.35b / FCF TTM 8.10b)
Total Stockholder Equity = -3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 6.38b / Total Assets 59.75b)
RoE = -161.9% (negative equity) (Net Income TTM 6.38b / Total Stockholder Equity -3.94b)
RoCE = 33.45% (EBIT 11.53b / Capital Employed (Equity -3.94b + L.T.Debt 38.40b))
RoIC = 22.63% (NOPAT 9.10b / Invested Capital 40.21b)
WACC = 5.32% (E(111.45b)/V(157.80b) * Re(7.13%) + D(46.35b)/V(157.80b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.44%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈7.21b ; Y1≈8.25b ; Y5≈11.48b
Fair Price DCF = 869.4 (DCF Value 198.39b / Shares Outstanding 228.2m; 5y FCF grow 16.94% → 3.0% )
EPS Correlation: 85.50 | EPS CAGR: 12.87% | SUE: 3.43 | # QB: 3
Revenue Correlation: 97.85 | Revenue CAGR: 6.63% | SUE: 1.97 | # QB: 1

Additional Sources for HCA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle